ABSTRACT
Background Health conditions and immune dysfunction associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19 once infected by SARS-CoV-2.
Methods The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers/family members on patients with COVID-19 and DS (N=1046). De-identified survey data collected between April and October 2020 were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. COVID-19 patients with DS from the ISARIC4C survey (ISARIC4C DS cases=100) were matched to a random set of patients without DS (ISARIC4C controls=400) and hospitalized DS cases in the T21RS survey (T21RS DS cases=100) based on age, gender, and ethnicity.
Finding The mean age in the T21RS survey was 29 years (SD=18), 73% lived with their family. Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Pain and nausea were reported less frequently (p<0.01), whereas altered consciousness/confusion were reported more frequently (p<0.01). Risk factors for hospitalization and mortality were similar to the general population (age, male gender, diabetes, obesity, dementia) with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher than for controls (T21RS DS versus controls: risk ratio (RR)=3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus controls: RR=2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality.
Interpretation Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of mortality, especially from age 40.
Funding Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, Matthews Foundation, National Down Syndrome Society, National Task Group on Intellectual Disabilities and Dementia Practices.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Trisomy 21 Research Society (T21RS) COVID-19 Taskforce developed the survey, with the financial and dissemination support of Down Syndrome Affiliates in Action (DSAIA), Down Syndrome Medical Interest Group-USA (DSMIG-USA), GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, Matthews Foundation, National Down Syndrome Society (NDSS), and the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). These and other international Down syndrome organizations are members of the T21RS COVID-19 stakeholders advisory group that provided advice to inform the design of the survey questions and interpretation of results, including the Global Down Syndrome Foundation (USA), DSA (UK), DSMIG (UK), DSMIG (USA), DSRF-UK, DSi, DSE international, Trisomie21-France, Down Espana, National Down Syndrome Congress (NDSC), Down Madrid, Fundacio Catalana Sindrome de Down (Spain), EDSA, Royal College of Psychiatrists, CoorDown (Italy), Associazione Italiana Persone Down (AIPD; Italy), AFRT (France), Fundacion Iberoamericana Down 21 (Spain), FIADOWN (Latin America), Federacao Brasileira das Associacoes de Sindrome de Down (Brazil) and the European Down Syndrome Association. We acknowledge the contribution of DS-Connect (The Down Syndrome Registry) which is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH for the dissemination of the T21RS survey. We also wish to thank the many families and clinicians who contributed to the survey. This report is independent research which used data provided by the MRC funded ISARIC 4C Consortium and which the Consortium collected under a research contract funded by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the ISARIC 4C consortium. AH is supported by the HERCULES Center (NIEHS P30ES019776) and the LuMind IDSC Foundation. The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). ACSC is supported by the Alana USA Foundation, Awakening Angels Foundation, and the Infectious Diseases Society of America (IDSA). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, DURSI 2017SGR595, and acknowledges the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21- 848077). ML was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a 'Unidad de Excelencia María de Maeztu', funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). This study was also supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI18/00335 to MCI, PI14/01126 and PI17/01019 to JF), partly jointly funded by Fondo Europeo de Desarrollo Regional, Union Europea, Una manera de hacer Europa; the Jerome Lejeune Foundation (No.1319 Cycle 2019B to MCI); the National Institutes of Health (NIA grants 1R01AG056850 - 01A1; R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, Pla Estrategic de Recerca i Innovacio en Salut (SLT006/17/00119 to JF); and Fundacio La Marato de TV3 (20141210 to JF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Each institution that planned to disseminate the survey within health services obtained IRB/ethics approval (Table S1).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data code books for the caregiver/family and clinician T21RS survey are provided in Supplementary Materials. The REDCap data dictionary can be provided on request to the corresponding author. Written requests for the use of the anonymized data collected through the T21RS survey will be reviewed for approval by the T21RS COVID-19 Initiative.
